未找到相关数据
Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma
被引：0
作者：
Chapman, P. B.
Hauschild, A.
Robert, C.
Larkin, J. M. G.
Haanen, J. B. A. G.
Ribas, A.
Hogg, D.
O'Day, S.
Ascierto, P. A.
Testori, A.
Lorigan, P.
Dummer, R.
Sosman, J. A.
Garbe, C.
Lee, R. J.
Nolop, K. B.
Nelson, B.
Hou, J.
Flaherty, K. T.
McArthur, G. A.
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Univ Klinikum Schleswig Holstein, Kiel Schleswig Holstein, Germany
[3] Canc Inst Gustave Roussy, Villejuif, France
[4] Royal Marsden Hosp, Urol Unit, London SW3 6JJ, England
[5] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Amsterdam, Netherlands
[6] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA
[7] Princess Margaret Hosp, Dept Med Oncol, Toronto, ON M4X 1K9, Canada
[8] Univ Toronto, Toronto, ON, Canada
[9] Angeles Clin & Res Inst, Los Angeles, CA USA
[10] Ist Nazl Tumori, Naples, Italy
[11] European Inst Oncol, Milan, Italy
[12] Christie Hosp, Manchester, Lancs, England
[13] Univ Zurich Hosp, CH-8091 Zurich, Switzerland
[14] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[15] Univ Tubingen, Tubingen, Germany
[16] Hoffmann La Roche Inc, Pharma Res & Early Dev, Nutley, NJ 07110 USA
[17] Plexxikon Inc, Berkeley, CA USA
[18] Genentech Inc, San Francisco, CA 94080 USA
[19] Massachusetts Gen Hosp, Boston, MA 02114 USA
[20] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Australia
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA4
引用
收藏
页数：1
相关论文